Search Results

KSQ Therapeutics, Inc., a clinical-stage biotechnology company developing treatments for solid tumors, announced the first patient dosed in the Phase 1/2 clinical study of KSQ-001EX, a novel edited TIL therapy.

KSQ Therapeutics, Inc. in collaboration with The University of Texas MD Anderson Cancer Center and the Cell Therapy Manufacturing Center (CTMC), today announced the Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for a Phase 1/2 clinical study of KSQ-001EX.

KSQ Therapeutics, Inc. announced today it has entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of KSQ-4279.

KSQ Therapeutics, Inc. and CTMC, a joint venture between National Resilience, Inc. and MD Anderson Cancer Center, announced a strategic collaboration to expedite the development of KSQ’s two lead engineered tumor-infiltrating lymphocyte programs, KSQ-001EX and KSQ-004EX, both of which are advancing toward clinical studies for the treatment of solid tumors.

KSQ Therapeutics Announces Ono Pharmaceutical Co., Ltd. is Acquiring Multiple Research-Stage Oncology Programs Identified with KSQ’s CRISPRomics ® Platform Technology.

KSQ Therapeutics, a clinical-stage biotechnology company developing cancer therapies using its proprietary CRISPRomics® discovery platform, announced that it has expanded its strategic collaboration with Takeda to research and validate novel tumor-intrinsic targets.

KSQ Therapeutics today announced the initiation of dosing in the combination therapy portion of Study KSQ-4279-1101, a Phase 1 clinical study of KSQ-4279 in patients with advanced solid tumors.

KSQ Therapeutics today announced the appointment of Mahesh Karande, President and CEO of Omega Therapeutics, to the company’s board of directors.

KSQ Therapeutics today named Micah Benson, PhD as the new Chief Scientific Officer (CSO) and announced the addition of a new Chief Technology Officer (CTO), Tom Leitch, to the KSQ leadership team.

KSQ Therapeutics (KSQ), a clinical-stage biotechnology company developing therapies to treat cancer and autoimmune diseases using its proprietary, integrated discovery CRISPRomics® platform, will give an oral presentation as part of the “New Drugs on the Horizon: Part 1” session at the upcoming American Association for Cancer Research (AACR) 2022 Annual Meeting in New Orleans.